-Reuters
Y-mAbs Announces Partnership Regarding Early Access Program For DANYELZA In Europe
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic